[18F]PSMA-1007 PET/CT 对中高危前列腺癌患者淋巴结转移原发分期的准确性评估
本研究为三级转诊中心回顾性队列,纳入2019年5月至2021年8月间接受机器人辅助腹腔镜前列腺根治术联合扩大盆腔淋巴结清扫的中高危前列腺癌患者104例,评估[18F]PSMA-1007 PET/CT术前分期的诊断准确性。全队列灵敏度26.9%(95%CI 11.6-47.8)、特异度96.2%(95%CI 89.2-99.2),对≥3 mm淋巴结转移灵敏度53.8%(95%CI 25.1-80.8)、特异度96.7%(95%CI 90.7-99.3)。结论认为该显像对淋巴结转移预测特异度高,但检出小于3 mm转移的灵敏度有限,不能完全替代扩大盆腔淋巴结清扫。
要点
- 全队列104例中26例病理证实淋巴结转移,其中13例(50%)转移灶≥3 mm。
- [18F]PSMA-1007 PET/CT全队列灵敏度26.9%、特异度96.2%,PPV 70%、NPV 93.6%。
- 对≥3 mm淋巴结转移灵敏度53.8%、特异度96.7%,检出小转移灶不可靠。
核心结论
- 在中高危前列腺癌原发分期中,[18F]PSMA-1007 PET/CT对淋巴结转移预测特异度高,但检出小于3 mm转移的灵敏度有限。
- 基于本研究结果,[18F]PSMA-1007 PET/CT不能完全替代扩大盆腔淋巴结清扫。
- 本研究发现该显像方法发现小转移灶不可靠。
研究设计与样本
- 研究为三级转诊中心的回顾性队列。
- 纳入2019年5月至2021年8月间因中危或高危前列腺癌接受手术治疗的前列腺癌男性患者。
- 干预为[18F]PSMA-1007 PET/CT初始分期后行机器人辅助腹腔镜前列腺根治术联合扩大盆腔淋巴结清扫。
- 共104例患者纳入分析。
主要发现
- 104例中26例根据病理报告存在淋巴结转移,其中13例(50%)转移灶≥3 mm。
- 全队列[18F]PSMA-1007 PET/CT灵敏度26.9%(95%CI 11.6-47.8)、特异度96.2%(95%CI 89.2-99.2)。
- 检出≥3 mm淋巴结转移的灵敏度53.8%(95%CI 25.1-80.8)、特异度96.7%(95%CI 90.7-99.3)。
- PPV为70%,NPV为93.6%。
关键数值与推荐
- 全队列灵敏度26.9%(95%CI 11.6-47.8)、特异度96.2%(95%CI 89.2-99.2)。
- ≥3 mm淋巴结转移灵敏度53.8%(95%CI 25.1-80.8)、特异度96.7%(95%CI 90.7-99.3)。
- PPV 70%,NPV 93.6%。
临床怎么用
- 作者基于本研究结果认为,[18F]PSMA-1007 PET/CT不能完全替代扩大盆腔淋巴结清扫。
- 作者指出该显像方法发现小转移灶不可靠。
局限性
- 研究为回顾性队列。
- 研究在单一三级转诊中心进行。
- 全队列灵敏度95%CI为11.6-47.8,区间较宽。
- ≥3 mm亚组灵敏度95%CI为25.1-80.8,区间较宽。
- 作者结论指出[18F]PSMA-1007 PET/CT不能完全替代扩大盆腔淋巴结清扫,且发现小转移灶不可靠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: [18F]PSMA-1007 is a promising tracer for integrated positron emission tomography and computed tomography (PET/CT). OBJECTIVE: Our aim was to assess the diagnostic accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastasis before robotic-assisted laparoscopy (RALP) with extended lymph node dissection (ePLND). DESIGN, SETTING AND PARTICIPANTS: The study was a retrospective cohort in a tertiary referral center. Men with prostate cancer that underwent surgical treatment for intermediate- or high-risk prostate cancer between May 2019 and August 2021 were included. INTERVENTIONS: [18F]PSMA-1007 PET/CT for initial staging followed by RALP and ePLND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Sensitivity and specificity were calculated both for the entire cohort and for patients with lymph node metastasis ≥ 3 mm. Positive (PPV) and negative (NPV) predictive values were calculated. RESULTS AND LIMITATIONS: Among 104 patients included in the analyses, 26 patients had lymph node metastasis based on pathology reporting and metastases were ≥ 3 mm in size in 13 of the cases (50%). In the entire cohort, the sensitivity and specificity of [18F]PSMA-1007 were 26.9% (95% confidence interval (CI); 11.6-47.8) and 96.2% (95% CI; 89.2-99.2), respectively. The sensitivity and specificity of [18F]PSMA-1007 to detect a lymph node metastasis ≥ 3 mm on PET/CT were 53.8% (95% CI; 25.1-80.8) and 96.7% (95% CI; 90.7-99.3), respectively. PPV was 70% and NPV 93.6%. CONCLUSIONS: In primary staging of intermediate- and high-risk prostate cancer, [18F]PSMA-1007 PET/CT is highly specific for prediction of lymph node metastases, but the sensitivity for detection of metastases smaller than 3 mm is limited. Based on our results, [18F]PSMA-1007 PET/CT cannot completely replace ePLND. This study investigated the use of an imaging method based on a prostate antigen-specific radiopharmaceutical tracer to detect lymph node prostate cancer metastasis. We found that it is unreliable to discover small metastasis.
引用
- Ingvar J, Hvittfeldt E, Trägårdh E, et al. Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Res. 2022. PMID: 35943665. doi:10.1186/s13550-022-00918-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。